Back to search

Article

Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1

2025-08-20

Abstract excerpt

<title>Abstract</title> <p>Intravenous anti-CTLA4 with anti-PD1 provides durable tumor responses but generates high rates of severe immune-related adverse events (irAEs) in cancer patients1-3. As opposed to anti-PD1 antibodies, anti-CTLA4 efficacy and toxicity is dose dependent, which limits its use in many patients and restricts broader application, particularly in localized cancers. Therefore, administering low...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5fa5592a-76ea-52e6-b643-7524b559ddb7
DOI
10.21203/rs.3.rs-7394486/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1DOI 10.21203/rs.3.rs-7394486/v1
The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity
Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity
Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical SettingSemantic proximity
Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlightsSemantic proximity
Advances in cancer immunotherapy: historical perspectives, current developments, and future directionsSemantic proximity
Immune Checkpoints are Predominantly Co-Expressed by Clonally Expanded CD4+FoxP3+ Intratumoral T-cells in Primary Human CancersSemantic proximity
Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanomaSemantic proximity
Tumor Immune Cell Infiltration Patterns and Predictable Clinical Benefit with Nivolumab in Combination with Ipilimumab for 3P ImplementationSemantic proximity
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).Semantic proximity
Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review)Semantic proximity
Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity
Immune Cell–Cytokine Interplay in NSCLC and Melanoma: A Pilot Longitudinal Study of Dynamic Biomarker InteractionsSemantic proximity
Select a neighboring publication to make it the new centre.